The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Update: Biosiomilar to Adalimumab Receives FDA Approval

FDA Update: Biosiomilar to Adalimumab Receives FDA Approval

September 6, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) approved adalimumab-adbm, a biosimilar to adalimumab, to treat multiple chronic inflammatory diseases. Also, the makers of baricitinib expect to re-file its application for the treatment of rheumatoid arthritis (RA) with the FDA in 2018.

You Might Also Like
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
Also By This Author
  • Phase 3 Results for Olokizumab in RA Patients

FDA Approves Adalimumab-adbm
On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a pre-filled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate to severe polyarticular juvenile idiopathic arthritis in patients age four years and older, moderate to severe active adult Crohn’s disease and moderate to severe active ulcerative colitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Cyltezo is not yet commercially available, and its maker, Boehringer Ingelheim, is currently engaged in patent litigation with AbbVie, which manufactures Humira.

Baricitinib’s Status
According to Eli Lilly and Co. and Incyte Corp., the makers of baricitinib, the new drug application for baricitinib will be refiled with the FDA before the end of January 2018.2 This resubmission will included new safety and efficacy data. Baricitinib is a once-daily oral investigational drug for treating patients with moderate to severe RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In April 2017, baricitinib’s potential approval to treat RA in the U.S. stalled when the FDA sent a complete response letter to the previous new drug application. The FDA declined to approve the treatment, citing that additional clinical data were needed to determine the most appropriate doses and the need for additional data to further characterize safety concerns.3 Baricitinib was approved for use in the European Union in February 2017 and in Japan in July 2017.

Additionally, baricitinib is being studied to treat atopic dermatitis and systemic lupus erythematosus. Phase 3 clinical trials for psoriatic arthritis are scheduled to begin in 2018.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Boehringer Ingelheim Pharmaceuticals Inc. News release: Boehringer Ingelheim Pharmaceuticals Inc. receives FDA approval for Cyltezo (adalimumab-adbm), a biosimilar to Humira, for the treatment of multiple chronic inflammatory diseases. 2017 Aug 29.
  2. Eli Lilly and Co. News release: Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018. 2017 Aug 30.
  3. Eli Lilly and Co. News release: U.S. FDA issues complete response letter for baricitinib. 2017 Apr 14.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, adalimumab-adbm, baricitinib, FDA, Food and Drug Administration, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration

You Might Also Like:
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.